Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. - Wikidata - awgldk - TriplyDB

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

http://www.wikidata.org/entity/Q36643661

about

Engineering opportunities in cancer immunotherapy Tumor infiltrating lymphocytes in ovarian cancer Trial watch: Dendritic cell-based anticancer therapy Targeting the tumor vasculature to enhance T cell activity Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment Combinations in multimodality treatments and clinical outcomes during cancer Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Why should we need the gut microbiota to respond to cancer therapies?A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Dendritic-cell-based therapeutic cancer vaccines Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines Epithelial ovarian cancer: An overview.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study Classification of current anticancer immunotherapies Immunotherapy for ovarian cancer.A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.Immunotherapeutic approaches to ovarian cancer treatment.A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma.Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma.Advances and prospects in adoptive cell transfer therapy for ovarian cancer Opportunities in immunotherapy of ovarian cancer.Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer Therapeutic targets and new directions for antibodies developed for ovarian cancer.Human dendritic cell subsets in vaccination.Ovarian cancer biology and immunotherapy.Metronomics: towards personalized chemotherapy?Targeting human dendritic cells in situ to improve vaccines.Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.

P2860

Q26776373-D9299B8A-BA91-441B-B833-96E1C9116C25 Q27021878-5A29CBD1-42A6-487C-909C-0684ABE16837 Q27024047-1A6AE10D-95B6-4AD9-8DA7-6197DBEF8A99 Q27026329-1C5F4EAF-093D-43DE-92AB-54B082AB492F Q27686800-9B5F3361-5BA3-47A0-A8AD-84CFB6C0E2A6 Q28067939-EDD25B9E-A3C9-4ED5-814A-85D4B0D91723 Q28392626-DEA6435B-C5A5-4C01-8EF2-2B52C55DE460 Q28393599-A724FDBD-ABCA-47A2-86FD-E482EAD1ADE3 Q28468623-8AC2DA87-E51C-485F-9E8A-7C4F6AD774DC Q29248711-17793B97-6FF6-43F2-AC4A-94EFAE0D60DA Q33357295-503310C0-7E6D-4BA8-9D3F-E17765D1E19A Q33553530-0F9BC344-D450-43EF-BF0A-2E64393873A4 Q33724878-4970E050-84B7-49C8-AE21-1A3C809825A0 Q34292741-B0B76F43-DB10-4683-A52C-B8C8BEE92DBE Q34360094-D53F76CB-2F6D-4DE7-A800-85DEEDA0F212 Q34477358-E80F9CF0-962B-4986-8630-92D936A00CE2 Q34708560-C414A1CA-DA86-43F3-9335-AD135B4FDA94 Q34993605-33E74071-3CDD-431A-A724-310802C18EDD Q35149637-DEC09AED-B268-44B5-897A-990628258F6C Q35164189-DE3630FB-0B19-4B7F-A805-C4D6885271C6 Q35201915-87F8CD6C-FAF1-42CA-A60F-1315443F62B8 Q35213535-6A333447-5752-4736-B2B4-027EA0D51764 Q35475233-4C4EDE47-1291-496F-9F09-5ECDB8E76981 Q35620238-600A7B10-EEDC-4102-B127-404CA2AC761B Q35761001-FB2EEA66-8D57-4CFF-941B-DFF412358D0F Q36302848-B43EE3E5-29EC-4220-815E-8CB8336C9696 Q36520189-4F19C82A-197E-4B00-BF28-86C6C1C77DB7 Q36852332-6D42B7C7-8272-43AA-BA08-2B2CEB471250 Q36855245-1DAE869E-123B-4178-83B5-5C225C26E91D Q36977760-4ED5BC39-0861-4192-8988-14FFB8A1C002 Q37106823-52106A87-39A8-4452-9CAE-4C891637597D Q37180279-C49962C3-ABDA-4720-BCDD-EA876B575D5E Q37203399-437910DD-E777-4E49-8193-0721B12E1348 Q37365673-51952A18-3F21-4E6F-BD68-5A8B001ABA70 Q37397674-7CBE89FF-09EC-479B-B335-2A5969BD0A23 Q38110971-AC6812CC-8DD2-4AC9-B9F5-48570E56DB26 Q38218761-0DB0B195-2A7F-4A76-8B6F-85053090192B Q38218923-65DFAB7A-E399-4315-8667-EE9003F5478C Q38235001-3C88F567-3190-48C1-8CDC-710FC71E3167 Q38376598-1AD2C21B-C64E-4077-8983-278DEACFA21B

P2860

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

http://www.wikidata.org/entity/Q36643661

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@ast

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@en

type

label

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@ast

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@en

prefLabel

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@ast

Autologous lysate-pulsed dendr ...... s in recurrent ovarian cancer.

@en

P1433

Q36643661-6B165F92-CB4D-43B9-957D-5BCED4D59E18

P1476

Q36643661-02ABC3E3-9844-4AE3-B78E-6F497FFD51EC

P2093

Q36643661-26924CB0-AD99-4CA0-8779-298BFD184E1C

Q36643661-29CA2E6D-E7FE-420F-98D1-549507005E40

Q36643661-329C60E3-B83C-401C-8122-C931B44A2F98

Q36643661-54541D23-6BCA-4B05-B506-1D270C1B66E4

Q36643661-697F2585-24DE-44F2-900D-8FAFD6353DE2

Q36643661-7F6DAE5A-D1FC-4CC9-B61F-BE1027D828CB

Q36643661-84BBBB63-C73B-4D3F-B977-C3465A92A680

Q36643661-D456F85B-BC58-4DAA-9B59-5D284F54E43B

Q36643661-D4808F1A-03CF-48D5-B750-BA8C2252F6F2

Q36643661-E58D1058-09E7-4758-99AD-9A4D2E2805D1

P2860

Q36643661-0957B236-12DA-4126-A528-80141BB89A2B

Q36643661-1F6A34B0-AD1C-4B87-B9B0-EE836EE5ED89

Q36643661-2B3FDBCA-F228-4DDC-8492-CCEC8ED1F849

Q36643661-353E025B-DE36-4285-9A23-7D94F4223E99

Q36643661-3645D3AF-30E6-47F4-8E06-F3FFAC4DD4FD

Q36643661-74DD0E47-C6AA-4B2E-8A56-A7CE88BEF665

Q36643661-7569C0F7-D6F7-4FA1-8B03-11564059C7DF

Q36643661-7E8FE914-415E-4718-9681-EEA2574A2EB8

Q36643661-7F22EAD4-747F-4C98-B6EA-AAF80AAC1773

Q36643661-81BB5078-5641-48FD-A867-128A790B5CFF

P304

Q36643661-AD943F75-CB2E-4CD0-9A6D-8312AB02A7C7

P31

Q36643661-73D2D884-8D32-451A-BBDD-B18BE69CD83B

P356

Q36643661-FB505672-2D7B-4C0F-A9F7-08113F2A3CD1

P433

Q36643661-DFF510BC-81AF-48AB-962D-D2841DFB0AF7

P478

Q36643661-839AC608-1EB5-4DC7-B617-477CE176C3C0

P50

Q36643661-12181831-7C33-487E-9B0A-25C833BF2D7D

P577

Q36643661-2FB91A0F-9202-4F01-BA09-FA2D8B6F9165

P5875

Q36643661-D508C127-3F3E-4118-BF79-26E2CAF4D54A

P698

Q36643661-296D12D3-C124-4276-A430-C537CFACB8D7

P921

Q36643661-C23AEBF2-13A1-4F51-9564-57A260D4E459

P932

Q36643661-7727C37C-3FE9-4232-9EF4-64E93D74123D

P356

P1433

P1476

Autologous lysate-pulsed dendr ...... ls in recurrent ovarian cancer

@en

P2093

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Cheryl L Chiang

http://www.w3.org/2001/XMLSchema#string

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

Drew A Torigian

http://www.w3.org/2001/XMLSchema#string

Janos Tanyi

http://www.w3.org/2001/XMLSchema#string

Kathy Montone

http://www.w3.org/2001/XMLSchema#string

Lana E Kandalaft

http://www.w3.org/2001/XMLSchema#string

Marnix Bosch

http://www.w3.org/2001/XMLSchema#string

Rosemarie Mick

http://www.w3.org/2001/XMLSchema#string

P2860

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Endothelin B receptor, a new target in cancer immune therapy.

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Telomerase as a universal tumor-associated antigen for cancer immunotherapy.

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Immunotherapy for gynaecological malignancies.

P304

e22664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.22664

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236039005

http://www.w3.org/2001/XMLSchema#string

P698

23482679

http://www.w3.org/2001/XMLSchema#string

P921

P932

3583933

http://www.w3.org/2001/XMLSchema#string